Overview

Phase Ⅱ Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in Patients With Inoperable Metastatic Breast Cancer

Status:
Completed

Trial end date:
2011-09-01

Target enrollment:

Participant gender:

Summary

To investigate the efficacy, safety, and pharmacokinetics when R435 and paclitaxel are administered concomitantly to patients with metastatic breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Chugai Pharmaceutical

Treatments:

Albumin-Bound Paclitaxel
Bevacizumab
Paclitaxel